Using a new antiallergic drug Epinepta® in the treatment of seasonal allergic conjunctivitis. Clinical cases

Purpose: to evaluate the effect of a new antiallergic drug epinastine in the treatment of seasonal conjunctivitis as manifested in clinical cases.Materials and methods. 37 people (22 men and 15 women) were observed during spring exacerbation of the allergic conjunctivitis, from mid-March to the end of June. Indicators of the dynamics of subjective complaints, duration of treatment, clinical effectiveness, were thoroughly recorded; we also assessed how easy it was to stop using the treatment when the condition of the ocular surface returned to normal.Results. We identified four groups of patients depending on the course of the disease, clinical manifestations, and response to epinastine therapy. For each group, we analyze a most informative clinical case.Conclusions. In all of the cases, epinastine instillations brought about a quick and stable reduction of itching and eye discomfort, as well as normalization of the clinical condition of the conjunctiva.